Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Posted on June 15, 2016 by tsuperadmin -
NCT00269854 – A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn’s Disease Posted on June 15, 2016 by tsuperadmin -
NCT01190839 – Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence Posted on June 15, 2016 by tsuperadmin -
NCT01551290 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis Posted on February 25, 2016 by tsuperadmin -
NCT00004941 – A Placebo-controlled, Repeated-dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Enterocutaneous Fistulae as a Complication of Crohn’s Disease Posted on November 4, 2014 by tsuperadmin -
NCT00207766 – ACCENT II – A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN’S Disease Posted on November 4, 2014 by tsuperadmin -
NCT00207662 – ACCENT I – A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn’s Disease Posted on November 4, 2014 by tsuperadmin -
NCT00487539 – A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis Posted on September 22, 2014 by tsuperadmin -
NCT00336492 – A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Posted on September 22, 2014 by tsuperadmin -
NCT00094458 – Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE® (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease) Posted on September 22, 2014 by tsuperadmin -
The YODA Project